There remains a need to identify patients who will derive benefits from adjunctive techniques on top of pulmonary vein ...

The observed changes were favorable, but results may have been affected by better-than-normal care in the control arm.

In the trial, 20% of patients didn’t respond well to the PCSK9 inhibitor—could genetic markers be used to tailor therapy?

Two studies presented at AHA show the capacity of AI to improve sonographer accuracy, consistency, and workflow.

By targeting the TTR gene directly in the liver, the therapy “has opened up the door” to permanent treatment, says Sarah ...

In the Swedish survey, many patients said their sexual health was impaired, but few got the information they wanted.

The accuracy of a several popular consumer smart devices for detecting atrial fibrillation (AF) did not improve over a ...

The mixed, counterintuitive results hinder trial interpretation, but along with ARREST-AF, experts still see actionable ...

In positive early data from the RCT, sacubitril/valsartan given over 24 weeks reduced signs of heart damage in cancer ...

HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

Amidst discrepant SPRINT and ACCORD data, this study confirms the benefits seen in nondiabetics, Shawna Nesbitt says.

Part 2 of this 7,000-patient trial suffered from discontinuations and low event rates: still, early MRAs did not impact CV ...